Thrombocythemia

May 07, 2020

Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis

Aug 16, 2019

FDA approves treatment for patients with rare bone marrow disorder

Jun 17, 2019

Data Presented At 24 Congress of the European Hematology Association Demonstrates Clinical Safety, Early Efficacy of Imago BioSciences' IMG-7289 in Myelofibrosis Patients

Jun 17, 2019

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

Jun 04, 2019

Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

Oct 01, 2018

CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

Jul 18, 2018

CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

Jul 02, 2018

CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib